In a recent study in mice, PDE10A inhibition with TP-10 improved pathological cardiac remodelling.134 PDE10A inhibition has been clinically tested in schizophrenia and Huntington’s disease, proving that it is a safe target for drug treatment and a potential therapeutic option for diseases related to cardiac remodelling.134. This evidence concerns the gene PDE10A and Huntington disease.